FDA Approves Qiagen's Therascreen EGFR as CDx for Boehringer Ingelheim's NSCLC Drug | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved for marketing Qiagen's therascreen EGFR test as a companion diagnostic test for Boehringer Ingelheim's new targeted treatment for metastatic non-small cell lung cancer, Qiagen said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.